Clinical Scorecard: Reexamining Bone Health in Parathyroid Disorders: Insights from Epidemiological Studies, Surgical Interventions, and Novel Therapeutics

At a Glance

Key Highlights

• Hyperparathyroidism causes increased bone turnover favoring resorption, leading to decreased bone mineral density and risk of fractures.
• Hypoparathyroidism results in low bone remodeling with increased bone mineral density but altered microarchitecture and potential skeletal fragility.
• Parathyroidectomy is definitive for hyperparathyroidism; medical therapies like calcimimetics and antiresorptives are alternatives when surgery is not feasible.

Guideline-Based Recommendations

Diagnosis

• Measure serum calcium and PTH levels to detect parathyroid disorders early, often incidentally.
• Use clinical, laboratory, and imaging parameters to assess skeletal involvement and bone remodeling status.

Management

• Primary hyperparathyroidism: parathyroidectomy is the definitive treatment.
• Secondary hyperparathyroidism: address underlying causes of hypocalcemia; consider medical management.
• Hypoparathyroidism: first-line treatment with calcium and active vitamin D; recombinant human PTH reserved for refractory cases.
• Use calcimimetics and antiresorptive agents as medical alternatives when surgery is contraindicated or unsuccessful.

Monitoring & Follow-up

• Regular assessment of bone mineral density and skeletal microarchitecture to evaluate disease progression and treatment response.
• Monitor serum calcium, phosphate, and PTH levels to guide therapy adjustments.

Risks

• Hyperparathyroidism increases risk of osteitis fibrosa cystica and fragility fractures due to high bone turnover.
• Hypoparathyroidism may increase fracture risk despite elevated bone mineral density due to defective microarchitecture.
• Surgical complications and incomplete resolution of skeletal defects if parathyroidectomy is unsuccessful.

Patient & Prescribing Data

Patients with hyperparathyroidism or hypoparathyroidism requiring medical or surgical intervention

Parathyroidectomy improves skeletal defects in hyperparathyroidism; calcimimetics and antiresorptives offer alternatives. Recombinant PTH is effective in refractory hypoparathyroidism but reserved after conventional therapy.

Clinical Best Practices

• Early detection of parathyroid disorders through routine serum calcium and PTH measurements.
• Tailor treatment modality to disease type, severity, and patient surgical candidacy.
• Employ multidisciplinary approach including endocrinologists, surgeons, and bone specialists for optimal management.
• Use imaging and biochemical markers to monitor bone health and adjust therapy accordingly.

References

• Article Source